This announcement comes in anticipation of market authorization from the FDA, which Genetesis expects to see later this year.
Dr. Robert Takla joins as Chief Medical officer, where he will develop and lead clinical strategy while building out innovative partnerships with other key players within heart medicine.
Most recently, Dr. Takla served as the chair and medical director of Emergency Medicine at Ascension St. John Hospital in Detroit, Michigan.
Prior to joining a leadership team at Genetesis, Dr. Takla was an early proponent of the use of magnetocardiography in the emergency department and led several early trials researching the efficacy of MCG in the efficient diagnosis of acute heart disease.
Dr. Mazen Albaghdadi joins as vice president of Medical Affairs, where he will oversee the intersection of research and clinical science with the company's commercial activity.
Albaghdadi currently practices interventional cardiology in his positions as the director of Cardiac Catheterization Laboratory and Associate Program director of Cardiology Fellowship at Naples Heart Institute in Naples, Florida.
With over 50 publications to his name, Dr. Albaghdadi is a champion of early-stage medical devices with novel applications in cardiac science.
Kevin Hillsman joins as vice president of Market Access, where he will oversee the expansion of patient access to CardioFlux by establishing new reimbursement pathways and executing other key market access initiatives.
Hillsman's recent experiences include a successful stint within HeartFlow's Market Access team followed by time spent leading Market Access at Abbott Labs for their Cardiometabolic division.
In these roles, Hillsman demonstrated an ability to navigate the complex payor ecosystem surrounding both Medicare and commercial health plans, bridging the gap between health plans and medical device providers to increase patient access to innovative and impactful solutions supporting cardiac health.
Genetesis, Inc. is a medical imaging company redefining the way ischemic heart disease is detected and understood.
Clario partners with AWS on advancing clinical data analysis with generative AI
Langhua Pharmaceutical passes US FDA's on-site inspection
Abbott receives CE Mark for Volt Pulsed Field Ablation System to treat atrial fibrillation
Ionis announces partnership expansion with Sobi for global olezarsen commercialisation
BioCardia secures Japanese patent for Helix biotherapeutic delivery system
Doer Bio completes DR10624phase two clinical study enrolment
Kancera and Recardio sign letter of intent for licensing agreement
Novo Nordisk launches NovoCare Pharmacy to reduce Wegovy costs and expand access
Redx Pharma reports positive Phase 1 results for RXC008 in fibrostenotic Crohn's disease
Hims & Hers acquires Trybe Labs to expand at-home testing capabilities
TriNetX and Fujitsu form joint venture to enhance clinical research in Japan
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
BrainCool secures market approval for BrainCool System in Malaysia
Roche's blood test measuring Lp(a) in molar units receives US FDA 510(k) approval